Capsule Opacification

01/01/2017 - "Posterior capsule opacification developed in 15 eyes (39.5%) and was treated successfully with neodymium:YAG capsulotomy. "
06/01/2011 - "The Evaluation of Posterior Capsule Opacification (EPCO) area, EPCO score, and neodymium:YAG (Nd:YAG) capsulotomy rates were compared using digital photographs. "
11/01/2010 - "None of the 20 eyes (20.0%) with posterior capsule opacification required neodymium:YAG capsulotomy. "
02/01/2007 - "In 31 eyes (23.7%), posterior capsule opacification required neodymium:YAG capsulotomy. "
09/01/2001 - "Posterior capsule opacification was also measured by the rate of neodymium:YAG (Nd:YAG) capsulotomies. "

01/01/2019 - "The purpose of this study was to investigate risk factors associated with development of clinically significant posterior capsule opacification requiring yttrium aluminum garnet (YAG) capsulotomy. "
01/01/2019 - "Factors Associated with the Development of Posterior Capsule Opacification Requiring Yttrium Aluminum Garnet Capsulotomy."
04/01/2007 - "Yttrium-Aluminum-Garnet (YAG) capsulotomy was performed in 3 eyes with secondary cataract. "
04/01/1992 - "Posterior capsule opacification occurred in 14 (60%) of the ECCE eyes, with five requiring Nd:YAG (Yttrium-Aluminum-Garnet) laser capsulotomies. "
10/16/2023 - "Nd:YAG (neodymium:yttrium-aluminum-garnet) capsulotomy (Nd:YAG-caps) is the gold standard for the treatment of PCO (Posterior Capsule Opacification). "

09/01/2009 - "Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification."
01/01/2021 - "Further studies with continuous data also revealed that the use of capsule tension ring was associated with a lower posterior capsule opacification score (SMD = -1.402, 95% CI: -2.448, -0.355 I2=95.0%). "
01/01/2021 - "Studies have suggested that the introduction of a capsule tension ring might play a critical role in the prevention of capsule opacification, yet quantitative evidence is still lacking. "
11/01/2019 - "In order to study the mechanisms involved in the development of posterior capsule opacification (PCO) we compared in vivo developed PCO with PCO formed in tissue culture with focus on the periphery of the lens capsule to evaluate lens regeneration potential. "
09/18/2014 - "Clinical studies show that IOLs with a square edge profile and complete contact between the IOL and the anterior capsule (AC) are currently the best way to prevent posterior capsule opacification (PCO). "

01/01/2002 - "The study presents the correlations concerning the advent of the secondary cataract depending on the surgical technique and pseudofak type (PMMA, acrylic, siliconic), as well the safety and efficacy of the YAG: Nd capsulotomy. "
06/01/2007 - "Prevention of posterior capsule opacification using round-edged PMMA IOL."
01/01/2005 - "The PMMA and the acrylic groups did not differ with respect to postoperative complications, but those eyes with an acrylic IOL had a lower rate of posterior capsule opacification."
01/01/2003 - "In the short-term follow-up, but not longer than within first 12 months after surgery the frequency of clinically significant posterior capsule opacification (PCO) was less in the HSM-PMMA group (8%), than in the PMMA group (33%), p = 0.006. "
03/01/2001 - "In vivo, implantation of P-32-labeled PMMA rings led to inhibition of epithelial cell proliferation and secondary cataract formation but was not able to fully inhibit aberrant differentiation of some remaining cells. "

01/01/2015 - "Round-edged silicone IOLs may also retard posterior capsule opacification formation, though not as much as sharp-edged IOLs. "
12/01/2002 - "Posterior capsule opacification developed in 48 eyes (34.2%), with the highest incidence in the silicone group. "
01/01/2002 - "Posterior capsule opacification of the central 3.0 mm area was lowest in the groups with a sharp-edged optic (CeeOn 911A, AcrySof) followed by the round-edged silicone (CeeOn 920), hydrophobic acrylic (AR40), and hydrophilic acrylic IOLs (P =.0001). "
01/01/2000 - "The fellow eye had a different style silicone IOL, which induced no visual side effects but was associated with early posterior capsule opacification."
07/01/1995 - "Our special interest is focussed on biocompatibility, formation of secondary cataract, biological reactions in the interface and the possibility of atraumatic explantation of the silicone lens."

01/01/2002 - "To evaluate the efficacy of an intracapsular ring releasing 5-fluorouracil (5-FU) in preventing posterior capsule opacification (PCO) in rabbit eyes. "
01/01/1998 - "To assess the efficacy of a control drug release implant coated with 5-Fu placed in the capsular bag for the prevention of the secondary cataract."
01/01/2002 - "Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study."
01/01/1998 - "[Implantation of controlled-release 5-FU for the prevention of secondary cataract: preliminary study]."
01/01/1996 - "MC and 5-FU could be a promising alternative in the prevention of posterior capsule opacification."

12/01/1998 - "To assess the safety and effectiveness of an immunotoxin, MDX-RA, designed to inhibit posterior capsule opacification (PCO). "
12/01/1998 - "Inhibition of posterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results."
08/01/1998 - "Medarex is developing MDX-RA, an immunotoxin, for the potential prevention of secondary cataracts. "
02/01/1998 - "Of special interest are techniques for inhibiting posterior capsule opacification in pediatric patients by optic capture through a posterior capsulorhexis, the concept that sharp optic edges markedly decrease posterior capsule opacification as compared with round-edged implants, and promising work demonstrating that an immunotoxin may be effective in prevention of posterior capsule opacification."
08/01/2006 - "The successful cloning and expression of DT(389)-hbFGF immunotoxin lay a foundation for accelerating lens epithelial cells apoptosis and the targeting therapy toward posterior capsule opacification."

09/01/1994 - "[A cytological study of inhibition of secondary cataract with heparin]."
07/01/2015 - "Prospective Randomized Intraindividual Comparison of Posterior Capsule Opacification After Implantation of an IOL With and Without Heparin Surface Modification."
11/01/1994 - "[A clinical study of inhibition of secondary cataract with heparin]."
05/01/1993 - "The incidence of posterior capsule opacification was greater in the heparin-surface-modified group than in the surface-passivated and regular groups, but the difference was not statistically significant."
08/01/1992 - "The antiproliferative activity on BLEC in medium containing aqueous humor suggests that heparin is a valuable tool for the prevention of secondary cataract in vivo."

03/01/2013 - "Long-term (after 4 weeks) complications included migration of silicone oil into the anterior chamber, posterior capsule opacification, and decentered IOL. "
05/01/2007 - "The additional posterior capsule opacification showed a distinct pattern and localisation when compared to the use of 5000 mPas-silicone oil as tamponade."
04/01/1999 - "Postoperative posterior capsule opacification (PCO) was more common in study than in control eyes (51% versus 21%; P = .002), especially if expandable gas or silicone oil had been used at vitrectomy. "
01/01/2022 - "The segmented measurement of ALs by immersion B-scan shows comparable measurement accuracy with that of IOLMaster 500 in ultra-high myopia patients with severe cataract secondary to silicone oil filling and can obtain an ideal postoperative refractive state."
01/01/2001 - "The transpupillary silicone oil removal group had significantly less vitreous hemorrhage (0- 31.8%) and posterior capsule opacification (0-36.4%). "

01/01/2008 - "On clinical assessment, cyclosporin A was significantly effective in preventing posterior capsule opacification compared with controls (P = 0.0045). "
01/01/2008 - "The preliminary results indicate that cyclosporin A is effective in suppressing posterior capsule opacification in rabbits, yet requires further investigation."
05/01/2015 - "The purpose of this study was to determine the Cyclosporine A (CsA) dose and minimum drug delivery time needed to prevent posterior capsule opacification (PCO) in an ex vivo canine model and evaluate the mechanism of CsA-induced cell death. "
01/01/2008 - "Cyclosporin effectively inhibits posterior capsule opacification after phacoemulsification in rabbits: a preliminary study."
01/01/2008 - "To evaluate whether cyclosporin A prevents or reduce posterior capsule opacification after phacoemulsification surgery in rabbit eyes. "

01/01/2012 - "Good outcome was significantly related to urban residence, presence of an intraocular lens and absence of ocular co-morbidities or posterior capsule opacification. "
01/01/2004 - "The sharp-edge foldable intraocular lenses types (AcrySof MA3OBA, AcrySof SA3OAL, CeeOn 911A) showed statistically significant difference in posterior capsule opacification values in one-year follow-up time. "
11/01/2011 - "To assess the axial stability and posterior capsule opacification (PCO)-inhibiting efficacy of a microincision hydrophilic intraocular lens (IOL) (Idea 613 XC) and a standard hydrophobic open-loop acrylic IOL (Acrysof SA60AT). "
01/01/2022 - "To conduct a Meta-analysis pooling randomized controlled trials (RCTs) to compare hydrophobic with hydrophilic acrylic intraocular lenses in terms of posterior capsule opacification (PCO) development. "
01/01/2021 - "Reply to Comment on: Posterior Capsule Opacification With Two Hydrophobic Acrylic Intraocular Lenses: 3-Year Results of a Randomized Trial."

01/01/2020 - "The objective of this study was to assess the rate of posterior capsule opacification (PCO), under "real-life" conditions, as measured by rates of Nd:YAG laser intervention, rather than from a controlled study from which patients with conditions predisposing to PCO have been excluded. "
01/01/2019 - "Methodology: The authors conducted a prospective, descriptive study on pseudophakic eyes with posterior capsule opacification who underwent Nd:YAG laser capsulotomy. "
01/01/1999 - "The purpose of the study is to evaluate the modern possibilities of performed by laser YAG in secondary cataract. "
06/01/2023 - "Nd-YAG laser capsulotomy for posterior capsule opacification has no detectable effect on macular and optic nerve flows and vessel densities."
01/01/2023 - "Centers with the lowest and highest percentages of Nd:YAG laser capsulotomies were interviewed on their physician practice styles related to the development of posterior capsule opacification. "

09/01/2018 - "Laser capsulotomy is accepted as a standard and effective treatment for posterior capsule opacification. "
01/01/2002 - "YAG: Nd laser capsulotomy appears to be a safe and efficient method of treating secondary cataract; it improved visual acuity in all cases, if different ocular pathology had not influenced it."
12/01/2015 - "To evaluate the efficacy of a laser photolysis (LP) system in preventing posterior capsule opacification (PCO) in a human ex vivo PCO model. "
01/01/2018 - "To study molecular and morphological changes in lens epithelial cells following femtosecond laser-assisted and manually performed continuous curvilinear capsulotomy (CCC) in order to get information about these methods regarding their potential role in the induction of development of secondary cataract. "
01/01/2022 - "Laser reconstructive interventions for secondary cataract, as well as LIE, have a number of advantages over traditional surgery, but at the same time are associated with the risk of complications, including in the cornea. "

02/01/2012 - "At 3 years, there was no statistically significant between-group difference in the median Evaluation of Posterior Capsule Opacification score or area values in the capsulorhexis margin (P=.36 and P=.39, respectively) or in the central 3.0 mm optic area (P=.40 and P=.42, respectively). "
10/01/2011 - "The impact of capsulorhexis diameter, localization and shape on posterior capsule opacification."
01/01/2008 - "Visual acuity, anterior capsule opacification (ACO), capsulorrhexis/optic overlapping, and posterior capsule opacification (PCO) were evaluated. "
05/01/2007 - "Visual acuity, anterior capsule opacification (ACO), capsular folds, capsulorrhexis/optic overlapping and posterior capsule opacification (PCO) were evaluated. "
10/01/2006 - "The area of capsulorhexis aperture was determined with computer software, and capsule opacification was graded subjectively. "

01/01/2019 - "We reviewed the best-corrected visual acuity (BCVA), incidence of posterior capsule opacification (PCO), clinical features at the diagnosis of rhegmatogenous RD, and intraoperative or postoperative complications following posterior capsulotomy. "
11/01/2016 - "Primary posterior capsulotomy in adults with posterior capsule opacification."
05/01/2014 - "Twenty-seven uncomplicated YAG posterior capsulotomies were performed for posterior capsule opacification. "
11/01/2013 - "To determine the effect of posterior capsulotomy on macular thickness, intraocular pressure and endothelial cell loss in pseudophakic patients with posterior capsule opacification using the other eye of every patient as a control. "
07/01/2012 - "Through a pars plana incision, the ocutome is then used to perform a posterior capsulotomy to prevent late posterior capsule opacification. "